BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31781311)

  • 21. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
    Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
    Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
    [No Abstract]   [Full Text] [Related]  

  • 22. Identification of Potential Biomarkers From Hepatocellular Carcinoma With MT1 Deletion.
    Zhang R; Huang M; Wang H; Wu S; Yao J; Ge Y; Lu Y; Hu Q
    Pathol Oncol Res; 2021; 27():597527. PubMed ID: 34257549
    [No Abstract]   [Full Text] [Related]  

  • 23. A four-long noncoding RNA signature predicts survival of hepatocellular carcinoma patients.
    Jiang H; Zhao L; Chen Y; Sun L
    J Clin Lab Anal; 2020 Sep; 34(9):e23377. PubMed ID: 32474975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma.
    Li M; Luo RZ; Chen JW; Cao Y; Lu JB; He JH; Wu QL; Cai MY
    J Transl Med; 2011 Jan; 9():5. PubMed ID: 21205329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
    Zhao QJ; Zhang J; Xu L; Liu FF
    World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
    Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
    Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreased expression of PTPN12 correlates with tumor recurrence and poor survival of patients with hepatocellular carcinoma.
    Luo RZ; Cai PQ; Li M; Fu J; Zhang ZY; Chen JW; Cao Y; Yun JP; Xie D; Cai MY
    PLoS One; 2014; 9(1):e85592. PubMed ID: 24475046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eight-gene metabolic signature related with tumor-associated macrophages predicting overall survival for hepatocellular carcinoma.
    Huo J; Wu L; Zang Y; Dong H; Liu X; He F; Zhang X
    BMC Cancer; 2021 Jan; 21(1):31. PubMed ID: 33413205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic and prognostic value of lncRNA cancer susceptibility candidate 9 in hepatocellular carcinoma.
    Zeng YL; Guo ZY; Su HZ; Zhong FD; Jiang KQ; Yuan GD
    World J Gastroenterol; 2019 Dec; 25(48):6902-6915. PubMed ID: 31908394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High Trophinin-Associated Protein Expression Is an Independent Predictor of Poor Survival in Liver Cancer.
    Jiao Y; Li Y; Lu Z; Liu Y
    Dig Dis Sci; 2019 Jan; 64(1):137-143. PubMed ID: 30284652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma.
    Yu B; Ding Y; Liao X; Wang C; Wang B; Chen X
    Dig Dis Sci; 2019 Oct; 64(10):2878-2892. PubMed ID: 30949905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel prognostic models for identifying the risk of hepatocellular carcinoma based on epithelial-mesenchymal transition-associated genes.
    Xiong C; Wang G; Bai D
    Bioengineered; 2020 Dec; 11(1):1034-1046. PubMed ID: 32951492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Profiles of prognostic alternative splicing signature in hepatocellular carcinoma.
    Wu F; Chen Q; Liu C; Duan X; Hu J; Liu J; Cao H; Li W; Li H
    Cancer Med; 2020 Mar; 9(6):2171-2180. PubMed ID: 31975560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma.
    Li S; Huang J; Yang F; Zeng H; Tong Y; Li K
    Sci Rep; 2021 May; 11(1):11078. PubMed ID: 34040099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low expression of long noncoding RNA CTC-297N7.9 predicts poor prognosis in patients with hepatocellular carcinoma.
    Zhu S; Huang X; Zhang K; Tan W; Lin Z; He Q; Chen Y; Shang C
    Cancer Med; 2019 Dec; 8(18):7679-7692. PubMed ID: 31674731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification and validation of EPHX2 as a prognostic biomarker in hepatocellular carcinoma.
    Zhan K; Bai Y; Liao S; Chen H; Kuang L; Luo Q; Lv L; Qiu L; Mei Z
    Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34278494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aberrant FAM64A mRNA expression is an independent predictor of poor survival in pancreatic cancer.
    Jiao Y; Fu Z; Li Y; Zhang W; Liu Y
    PLoS One; 2019; 14(1):e0211291. PubMed ID: 30695070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
    Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
    World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma.
    Sueoka S; Kanda M; Sugimoto H; Shimizu D; Nomoto S; Oya H; Takami H; Ezaka K; Hashimoto R; Tanaka Y; Okamura Y; Yamada S; Fujii T; Nakayama G; Koike M; Fujiwara M; Kodera Y
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1453-60. PubMed ID: 25805236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological significance of miR-27b targeting Golgi protein 73 in patients with hepatocellular carcinoma.
    Liang H; Ai-Jun J; Ji-Zong Z; Jian-Bo H; Liang Z; Yong-Xiang Y; Chen Y
    Anticancer Drugs; 2019 Feb; 30(2):186-194. PubMed ID: 30418194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.